Navigation Links
Systemic Pre-Surgical Treatment Can Prolong Survival Of Kidney Cancer Patients

A preliminary result of The Phase II Clinical Trial conducted by a cancer institute in USA provides the first evidence on pre-surgical treatment // for kidney cancer with the help of bevacizumab and erlotinib[1], the results have also proved that the treatment is safe, effective and may help in prolonging patient's survival.

Renal cell carcinoma [2] (kidney cancer) is notoriously hard to treat, especially once it has started to spread to other sites in the body. If it has metastasised to the lymph nodes, five-year survival is between 5-15% and if it has spread to other organs the five-year survival is less than five per cent.

Studies have been carried out investigating the use of targeted therapies, such as bevacizumab and erlotinib, after surgery, but researchers at the University of Texas MD Anderson Cancer Center, USA, are conducting the first trial to investigate their use before surgery.

Assistant professor of medicine, Eric Jonasch, told a news briefing at the EORTC-NCI-AACR [3] Symposium on Molecular Targets and Cancer Therapeutics in Prague today (Thursday 9 November) that, as of June 2006, the 20 patients enrolled in the trial within the previous year were all still alive. One had complete remission in the primary tumour and stable disease in bone metastases, three patients were in partial remission, 13 patients had stable disease and three patients had progressive disease.

'Without this treatment I would have expected most of them to have progressive disease by now,' said Prof Jonasch. 'The average time to progressive disease is usually about twelve weeks, and I would argue that our patients have more aggressive disease as they have not had the benefit of any previous treatment.

'These early data suggest pre-surgical treatment with bevacizumab and erlotinib is safe and efficacious in patients with previously unresected, untreated metastatic renal cell carcinoma, with shrinkage of both the metastatic diseas
'"/>




Page: 1 2 3

Related medicine news :

1. Systemic Corticosteroid Therapy can be used for treating all types of Infectious Mononucleosis
2. New Treatment Offers Hope for Systemic Sclerosis
3. Advances in Treatment of Cataracts
4. Recommendations for Treatment of Blood Pressue
5. Treatment for Menieres disease
6. Treatment for pre-menstrual syndrome is ineffective
7. Better Treatment for obesity
8. Gene Treatment for Heart Disease
9. More People Seeking Treatment for Depression
10. Focused Treatment For Childhood Cancer
11. Inadequate Drug Treatment For Youth
Post Your Comments:
(Date:10/1/2014)... California (PRWEB) October 01, 2014 ... to benefit a very special cause. The campaign—“Buy ... support for Paws for Veterans, a nonprofit organization ... while also rescuing shelter dogs that would otherwise ... of featured products will support monthly donations of ...
(Date:10/1/2014)... October 01, 2014 Woodland Hills ... to a group of dental specialists who treat full ... Spain city of Oviedo. Dr. Reshad of the Anacapa ... with clients on two continents, will give a full-day ... full mouth reconstruction. , “These specialists want to improve ...
(Date:10/1/2014)... CA (PRWEB) October 01, 2014 Today ... the Anacapa Dental Art Institute in Oxnard and Woodland ... Bangalore providing full mouth rehabilitation training. , “Speaking to ... of these transformative procedures to get the help and ... rehabilitation may involve repairing previous dental work, providing cosmetic ...
(Date:10/1/2014)... DC (PRWEB) October 01, 2014 Generic ... all retail generics increasing in price in the last ... Services, Inc.’s (AIS) Drug Benefit News (DBN) interviewed a ... trend means for pharmacies and health plans. , ... with rising generic acquisition costs, these cost increases squeeze ...
(Date:10/1/2014)... Madison, Wi (PRWEB) October 01, 2014 ... sales of UP4 WOMEN’S probiotic to The National Network ... month of October. This organization was chosen through nationwide ... UP4’s website and social media outlets. , “We ... to receive a portion of every sale of UP4 ...
Breaking Medicine News(10 mins):Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 3Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 4Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 3Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 4Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 5Health News:Rising Generic Drug Prices Affect Pharmacies, Insurers Alike, Reports AIS Newsletter 2Health News:Rising Generic Drug Prices Affect Pharmacies, Insurers Alike, Reports AIS Newsletter 3Health News:UP4 Probiotics Partners with The National Network to End Domestic Violence 2
... 2008 Use of the drug interferon as a ... disease associated with the hepatitis C virus is ineffective, ... nine other institutions have found in a multicenter study. ... (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis) Trial, appear ...
... Corporation (NYSE: GTS ) today announced that it ... managed care assets of La Cruz,Azul de Puerto Rico, ... Association to transfer the licensing rights to the Blue Cross ... brands in the US Virgin Islands,to the Company and Triple-S, ...
... Available from NetLearning , ... Clifton ... leading provider of integrated e-learning solutions for healthcare training, compliance, ... pleased to announce the latest major release of the Learning ...
... medication used for high blood pressure does not improve ... results from a large, international study. , The ... Medical Center in key leadership positions, appears in this ... Medicine , published today. , The findings are disappointing ...
... finds , , THURSDAY, Dec. 4 (HealthDay News) -- Reactions ... are rare, and young women can tolerate subsequent doses. ... data after more than 380,000 doses of the Gardasil ... in April 2007. , Gardasil protects against four ...
... of Steven Sabock, a 50-year-old man with bipolar disorder who ... psychiatric institution after he choked on medication -- while, ... has focused attention on the crisis in North Carolina,s mental ... tragic, preventable death of Steven Sabock -- which made headlines ...
Cached Medicine News:Health News:HALT-C researchers: Interferon as long-term treatment for hepatitis C not effective 2Health News:Triple-S Management Corporation Signs Letter of Intent to Acquire Managed Care Portfolio of La Cruz Azul de Puerto Rico, Inc. 2Health News:NetLearning Releases Learning Administrator 7.1 for Online Professional Healthcare Training 2Health News:NetLearning Releases Learning Administrator 7.1 for Online Professional Healthcare Training 3Health News:Study finds treatment fails to improve common form of heart failure 2Health News:Study finds treatment fails to improve common form of heart failure 3Health News:Cervical Cancer Vaccine Well Tolerated 2Health News:Tragedy Focuses Spotlight on Crisis in North Carolina Mental Health System 2
(Date:10/1/2014)... Calif. , Oct. 1, 2014 /PRNewswire/ ... ), a clinical-stage biopharmaceutical company focused on ... positive results from its 371 patient Phase ... with constipation-predominant irritable bowel syndrome (IBS-C).  Results ... clinically meaningful improvement in IBS-C symptoms for ...
(Date:10/1/2014)... October 1, 2014 Sophia Genetics, ... Sequencing (NGS) data analysis, today launches a unique CFTR ... analysis in a single NGS experiment. The CE-IVD marked ... of variants in a single NGS experiment with clinical ... not been possible to simultaneously analyse all relevant CFTR ...
(Date:9/30/2014)... , Sept. 30, 2014  Wrightington, Wigan ... Allscripts (NASDAQ: MDRX ) are delighted to ... as WWL,s new health information system. The system will ... completely transform the way WWL delivers healthcare in the ... a demonstrated record of on-time and on-budget system implementations ...
Breaking Medicine Technology:Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4
... /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain Drugstore Ltd. (NYSE: ... largest drugstore chain in China based on the number ... will report its third quarter 2010 financial results on ... The Company will host a conference call, to ...
... Tibotec Announced Week 24 Interim Results From Phase... -- HUDDINGE, Sweden, November 1, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Medicine Technology:China Nepstar Chain Drugstore to Report Third Quarter 2010 Financial Results on November 17, 2010 2Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 2Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 3Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 4Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 5Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 6Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 7Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 8Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 9Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 10Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 11Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 12Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 13
Full Handle Laseredge Implant Blade Knife, 4.0 mm straight. Blade dimension: 15.2 mm x 4.0 mm x 3.0 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, straight. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 45 blade. Blade tip dimension: 8.9 mm x 1.9 mm x 1.9 mm....
Full Handle Laseredge Stab Blade Knife, 15 blade. Blade tip dimension: 11.1 mm x 1.5 mm x 5.7 mm....
Medicine Products: